• Home
  •  / UNITY Biotechnology

UNITY Biotechnology

OverviewSuggest Edit

Unity Biotechnology designs therapeutics that prevent various diseases of aging. The company focuses on clearing senescent cells and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected.
TypePublic
Founded2009
HQSouth San Francisco, CA, USMap
Websiteunitybiotechnology.com
Employee Ratings3.3More
Overall CultureC+More
View Jobs (6)

Recent NewsAll News

Latest Updates

Employees (est.) (Mar 2020)98
Job Openings6
Share Price (Jul 2021)$3.6(-5%)
Cybersecurity ratingAMore

Key People/Management at UNITY Biotechnology

Anirvan Ghosh

Anirvan Ghosh

Chief Executive Officer and Director
Nathaniel David

Nathaniel David

Co-Founder & Director
Lynne Sullivan

Lynne Sullivan

Chief Financial Officer
Jamie Dananberg

Jamie Dananberg

Chief Medical Officer
Susan Lundeen

Susan Lundeen

Chief Human Resources Officer
Jason Damiano

Jason Damiano

Vice President of Translational Biology
Show more

UNITY Biotechnology Office Locations

UNITY Biotechnology has an office in South San Francisco
South San Francisco, CA, US (HQ)
285 E Grand Ave
Show all (1)

UNITY Biotechnology Financials and Metrics

UNITY Biotechnology Revenue

USD

Net income (Q1, 2021)

(15.8m)

EBIT (Q1, 2021)

(14.9m)

Market capitalization (30-Jul-2021)

199.7m

Closing stock price (30-Jul-2021)

3.6

Cash (31-Mar-2021)

26.8m

EV

201.4m
UNITY Biotechnology's current market capitalization is $199.7 m.
Annual
USDFY, 2018FY, 2019FY, 2020

General and administrative expense

16.0m20.0m24.0m

R&D expense

58.9m71.0m67.3m

Operating expense total

74.9m91.0m91.3m

EBIT

(79.5m)(89.7m)(93.9m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

General and administrative expense

3.5m3.8m4.4m4.5m5.0m5.7m6.0m6.3m6.5m6.2m

R&D expense

13.0m15.2m14.4m16.5m18.5m17.8m19.3m16.1m18.8m8.7m

Operating expense total

16.5m19.0m18.7m21.0m23.4m23.5m25.2m22.4m25.4m14.9m

EBIT

(16.5m)(20.8m)(19.4m)(19.7m)(24.5m)(22.4m)(27.2m)(23.3m)(24.6m)(14.9m)
show all
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

15.4m37.5m17.8m

Prepaid Expenses

1.8m2.0m3.2m

Current Assets

173.0m129.5m100.9m

PP&E

6.2m16.6m12.6m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

62.8m34.2m28.9m34.2m23.1m36.8m25.1m39.6m48.6m26.8m

Prepaid Expenses

697.0k1.7m2.0m1.6m2.8m2.2m1.9m4.0m3.5m1.6m

Current Assets

136.4m187.6m179.8m151.8m141.4m125.9m115.2m123.5m135.7m102.0m

PP&E

6.6m6.6m6.3m5.9m5.7m5.4m15.1m14.2m13.5m11.9m
show all
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(76.4m)(82.2m)

Depreciation and Amortization

2.2m2.7m3.4m

Accounts Payable

2.2m(227.0k)(2.6m)

Cash From Operating Activities

(56.6m)(72.4m)(78.3m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(16.1m)(36.1m)(54.5m)(18.8m)(42.4m)(64.1m)(28.0m)(46.7m)(15.8m)

Depreciation and Amortization

502.0k1.0m1.6m637.0k1.3m1.9m903.0k1.8m2.6m757.0k

Accounts Payable

1.8m(633.0k)91.0k(776.0k)391.0k(331.0k)(1.3m)(1.3m)(966.0k)(640.0k)

Cash From Operating Activities

(11.9m)(29.9m)(43.8m)(20.6m)(39.9m)(56.7m)(25.1m)(44.4m)(61.6m)(15.1m)
show all
USDQ1, 2018

Financial Leverage

-1.5 x
Show all financial metrics

UNITY Biotechnology Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

Learn more about our premium products
SecurityScorecard logo

UNITY Biotechnology Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

UNITY Biotechnology Online and Social Media Presence

UNITY Biotechnology's Trends

Embed Graph

UNITY Biotechnology Company Culture

  • Overall Culture

    C+

    75/100

  • CEO Rating

    A+

    95/100

  • Compensation

    B

    78/100

Learn more on Comparably

UNITY Biotechnology News and Updates

July 23, 2021

UNITY Biotechnology to Host Investor Call with Retinal Expert Robert Bhisitkul, M.D., Ph.D., to Discuss Recent Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease

UNITY management team and Dr. Bhisitkul to discuss initial safety and efficacy data supporting improvements in vision and structure seen in patients treated with a single dose of UBX1325
July 06, 2021

UNITY Biotechnology Announces Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease

Improvement in Visual Acuity and Central Subfield Thickness observed in diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD) patients treated with UBX1325
May 11, 2021

UNITY Biotechnology, Inc. Reports First Quarter 2021 Financial Results and Business Updates

-  UBX1325 demonstrates favorable tolerability in Phase 1 safety study with initial evidence of relevant biological activity
May 01, 2021

UNITY Biotechnology Presents UBX1325 Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinical Models of Diabetic Retinopathy Eye Diseases

UBX1325’s selective elimination of senescent cells represents a novel approach for the treatment of diabetic retinopathy and macular edema
March 08, 2021

UNITY Biotechnology Announces Appointment of Alexander Nguyen as General Counsel

SOUTH SAN FRANCISCO, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that Alexander Nguyen has been appointed general counsel.
February 01, 2021

UNITY Biotechnology Appoints Mike Sapieha, Ph.D., as Chief Scientific Advisor

Mike Sapieha brings world-class expertise in aging-related ophthalmologic and neurologic diseases
Show more

UNITY Biotechnology Blogs

March 23, 2021

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Business Updates

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Business Updates Content Import Tue, 03/23/2021 - 16:01 UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Business Updates March 23, 2021 at 4:01…
March 11, 2021

UNITY Biotechnology Reports Granting of New Employment Inducement Award

UNITY Biotechnology Reports Granting of New Employment Inducement Award Content Import Thu, 03/11/2021 - 16:06 UNITY Biotechnology Reports Granting of New Employment Inducement Award March 11, 2021 at 4:05 PM EST This release is a backfill from a News Wire …
February 26, 2021

UNITY Biotechnology to Participate in Upcoming March Investor Conferences

SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that members of its senior management team will participate in the following
October 12, 2020

UNITY Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edema

SAN FRANCISCO , Oct. 12, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that the first patient has been dosed in a Phase 1 study of UBX1325
September 04, 2020

UNITY Biotechnology to Participate in Upcoming September Investor Conferences

SAN FRANCISCO , Sept. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team will participate in the
August 17, 2020

UNITY Biotechnology Announces 12-week data from UBX0101 Phase 2 Clinical Study in Patients with Painful Osteoarthritis of the Knee

UBX0101 failed to meet 12-week primary endpoint Guidance for UNITY’s Bcl-xL inhibitor UBX1325 in retinal disease remains unchanged UNITY to focus senescence programs on ophthalmologic and neurologic diseases in near-term UNITY to hold investor and analyst conference call today, Monday, August 17,
Show more

 UNITY Biotechnology Frequently Asked Questions

  • When was UNITY Biotechnology founded?

    UNITY Biotechnology was founded in 2009.

  • Who are UNITY Biotechnology key executives?

    UNITY Biotechnology's key executives are Anirvan Ghosh, Nathaniel David and Lynne Sullivan.

  • How many employees does UNITY Biotechnology have?

    UNITY Biotechnology has 98 employees.

  • Who are UNITY Biotechnology competitors?

    Competitors of UNITY Biotechnology include ITeos Therapeutics, Abiogen Pharma and PlasmaGen Biosciences.

  • Where is UNITY Biotechnology headquarters?

    UNITY Biotechnology headquarters is located at 285 E Grand Ave, South San Francisco.

  • Where are UNITY Biotechnology offices?

    UNITY Biotechnology has an office in South San Francisco.

  • How many offices does UNITY Biotechnology have?

    UNITY Biotechnology has 1 office.